Patents vs patients 1-0: The case of chenodeoxycholic acid

Sarah Marie Briké; Wouter Meersseman; David Cassiman

doi:10.1002/jimd.12443

Patents vs patients 1-0: The case of chenodeoxycholic acid

J Inherit Metab Dis. 2022 Mar;45(2):377-378. doi: 10.1002/jimd.12443. Epub 2021 Oct 6.

Authors

Sarah Marie Briké¹, Wouter Meersseman^{1

2}, David Cassiman¹

Affiliations

¹ Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium.
² Department of General Internal Medicine, KU Leuven, Leuven, Belgium.

PMID: 34599614
DOI: 10.1002/jimd.12443

Abstract

Profit-driven games with the availability and prices of chenodeoxycholic acid led to the discontinuation of proper treatment for this cerebrotendinous xanthomatosis patient with disastrous consequences to his health.

Keywords: CDCA; CTX; cerebrotendinous xanthomatosis; chenodeoxycholic acid; orphan drug; xanthoma.

MeSH terms

Chenodeoxycholic Acid* / therapeutic use
Humans
Xanthomatosis, Cerebrotendinous*

Substances

Chenodeoxycholic Acid